Introduction:
Chronic obstructive pulmonary disorder is a progressive inflammatory condition of the airways, mainly exposure to nitrous gases and particles. It limits the continuous airflow. Many inflammatory pathways pathologically mediate the condition. It is one of the leading causes of morbidity and mortality among adults. The primary inflammatory cells implicated in COPD include macrophages, neutrophils, dendritic cells, and CD 8+ T lymphocytes.
What Is COPD?
COPD is defined as a persistent restriction in airflow that is typically progressive and linked to an increased chronic inflammatory response in the lung and airways to noxious particles or gasses. It is a prevalent and avoidable condition. Airflow obstruction is defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as spirometry with a ratio of less than 0.705 between forced expiratory volume in the first second and forced vital capacity following bronchodilation.
The main feature of COPD is chronic inflammation, which is caused by a wide range of cells interacting with one another in the lung microenvironment. Cigarette smoke is thought to be a major etiological factor in the onset and pathophysiology of COPD because it causes chronic lung inflammation. After exposure to cigarette smoke, lung structural and inflammatory cells release proinflammatory mediators, which draw in more inflammatory immune cells and help create a chronic inflammatory milieu.
In addition to impairing innate and adaptive immune responses and causing lung damage, chronic inflammation makes it easier for respiratory infections to return and accentuate the clinical signs of stable illness.
What Are the Inflammatory Cells in COPD?
It has long been acknowledged that smoking-related inflammatory responses in the lung parenchyma and airways are the primary cause of COPD in smokers. When cigarette smoke binds to Toll-like receptors, it releases a danger signal that stimulates innate immune cells by producing cytokines and inducing innate inflammation. COPD is a result of compromised immune function, and infections that arise from these compromised immune responses aggravate the disease. The strength and duration of acute exacerbations of COPD indicate how well the adaptive immune system can control the body's natural defenses against infection (also called the Goldilocks hypothesis).
According to Goldilocks' theory, an infection can be successfully eradicated by the innate and adaptive immune system when the response is moderate and fleeting—that is, neither too strong nor too weak. The inflammatory immune alterations linked to COPD are associated with a process of tissue remodeling and repair that results in an increase in mucus production and emphysematous destruction of the lung's gas-exchanging surface. Numerous inflammatory cells, such as neutrophils, macrophages, T lymphocytes, and Dendritic Cells (DCs), are present in the irritated airways of COPD patients.
According to recent research, COPD patients also have higher populations of goblet cells24, which leads to hypersecretion and overproduction of mucus. The airway remodeling and parenchymal destruction typical of COPD are likely to occur only when all inflammatory cell types (i.e., CD4+, CD8+, neutrophils, and macrophages) are present in the lung. These cells release various substances that contribute to the development of chronic inflammation, including reactive oxygen species, chemokines (like interleukin [IL]-8), cytokines (like tumor necrosis factor-alpha [TNF-α]), and proteases (like neutrophil elastase [NE] and matrix metalloproteinase [MMP]).
How Is Innate Immunity Modulation In COPD?
The lung's innate immune defenses include the surfactant, complement components, antimicrobial peptides, epithelium barrier, and mucociliary clearance. Natural killer cells, neutrophils, mast cells, macrophages, Dendritic Cells (DCs), monocytes, and neutrophils are examples of immune cells that support lung immunity. Tissue immunity, which guards against infections, is strengthened by immune responses that are generated during typical inflammatory processes. Nevertheless, in individuals suffering from COPD, the inflammatory lung microenvironment and severity of the disease are exacerbated by the induction of compromised immune responses that lead to sporadic respiratory infections. Innate immune cells in COPD patients sense tissue destruction and respiratory infections in their lungs through pathways involving Damage-Associated Molecular Patterns (DAMP) and pathogen-associated molecular Pattern–Pattern Recognition Receptors (PRR). These are important in modulating host immune responses.
Phagocytes regulate infection and hasten the healing of inflammation brought on by infection. Alveolar macrophages phagocytose infiltrated neutrophils during an inflammatory response to manage the infection and regulate the degree of inflammation. Patients with COPD, however, have reduced functional cooperation. Despite increased alveolar macrophages in COPD patients, their phagocytic capacity is decreased compared to smokers without COPD. The increase in neutrophilic load in airways is caused by both the reduction of macrophage activity and the induction of neutrophil survival. In addition, alveolar monocyte precursors differentiate into the M2 macrophage phenotype due to CS. Due to their secretion of matrix metalloproteinases, higher numbers of M2 macrophages in COPD patients are correlated with decreased FEV, disease progression, and disease severity.
How Is Adaptive Immunity Modulation In COPD?
Individuals with COPD are more likely to experience repeated respiratory infections, which exacerbates the illness. In COPD, the adaptive immune system's capacity to mount a powerful defense against pathogens and its initial reaction to them is compromised. Those with compromised immune systems may experience recurrent infections. NTHI (Nontypeable haemophilus influenzae) is linked to increased lung inflammation and pathology related to the disease. It is a bacterial cause of exacerbations in COPD patients. Chronic nicotine exposure in mice induces T cell anergy, suppressing the immune system. In patients with COPD, diminished adaptive immune responses to respiratory pathogens colonizing their airways exacerbate the disease and recurrent lung infections. The three most frequent bacteria that cause exacerbations in COPD patients are Streptococcus pneumonia, Moraxella catarrhalis, and NTHI.
Conclusion:
A major contributing factor to COPD is chronic lung inflammation, which damages the lungs extensively and lowers resistance to respiratory infections. Systemic and lung-specific immune dysfunction linked to COPD can lead to exacerbations of the disease. Restoring immune function may also reduce tissue deterioration and inflammation brought on by infections and pathogen-mediated disease exacerbations. However, to reduce lung inflammation without sacrificing immunity against respiratory infections, a delicate balance between the induction of immunosuppressive networks and adaptive immunity is required. A deeper comprehension of the pathobiology of COPD should be the main goal of future research. To gain a deeper understanding of the traits and stability of these subgroups, these studies should incorporate a longitudinal analysis of the endotypes or biomarker-defined segmentations.
